Sensorion received authorization from France’s ANSM to initiate a Phase I/II trial of SENS-601 (GJB2-GT) for GJB2-related hearing loss, bringing the company’s lead gene therapy candidate into clinic. The decision supports early clinical evaluation of a genetic approach targeting a defined cause of congenital or early-onset hearing impairment. Separately, multiple RNA- and gene-based specialty assets are advancing through regulatory milestones, underscoring a continuing shift toward mechanism-first development in neurology and sensory disorders. The next inflection points will hinge on early safety signals and evidence of biological activity in the Phase I/II setting, which will determine how quickly these programs can scale into broader clinical pathways.